Barber P A, Zhang J, Demchuk A M, Hill M D, Buchan A M
Department of Clinical Neurosciences, University of Calgary, Alberta, Canada.
Neurology. 2001 Apr 24;56(8):1015-20. doi: 10.1212/wnl.56.8.1015.
Thrombolytic therapy for acute stroke (<3 hours) will not have a major impact on death and dependency unless it is accessible to more patients.
To determine why patients with ischemic stroke did not receive IV TPA and assess the availability of this therapy to patients with ischemic stroke.
Consecutive patients with acute ischemic stroke were prospectively identified at a university teaching hospital between October 1996 and December 1999. Additional patients with ischemic stroke were identified that were admitted to one of three other hospitals in the Calgary region during the study period. The Oxford Community Stroke Programme Classification was used to record type and side of stroke.
Of 2165 stroke patients presenting to the university hospital, 1168 (53.9%) were diagnosed with ischemic stroke, 31.8% with intracranial hemorrhage (intracerebral, subarachnoid, or subdural), and 13.9% with TIA. Delay in presentation to emergency department beyond 3 hours excluded 73.1% (854/1168). Major reasons for delay included uncertain time of onset (24.2%), patients waited to see if symptoms would improve (29%), delay caused by transfer from an outlying hospital (8.9%), and inaccessibility of treating hospital (5.7%). Twenty-seven percent of patients with ischemic stroke (314/1168) were admitted within 3 hours of sympton onset and of these 84 (26.7%) patients received IV TPA. The major reasons for exclusion in this group of patients (<3 hours) were mild stroke (13.1%), clinical improvement (18.2%), perceived protocol exclusions (13.6%), emergency department referral delay (8.9%), and significant comorbidity (8.3%). Of those patients who were considered too mild or were documented to have had significant improvement, 32% either remained dependent at hospital discharge or died during hospital admission. Throughout the region there was a total of 1806 ischemic stroke patients (admitted to all four Calgary hospitals). During this study period, 4.7% received IV TPA.
The majority of patients are unable to receive TPA for acute ischemic stroke because they do no not reach the hospital soon enough. Of those patients presenting within 3 hours, 27% received the therapy but a further 31% were excluded because their symptoms were either considered too mild or were rapidly improving. Subsequently, a third of these patients were left either dependent or dead, bringing into question the initial decision not to treat.
急性卒中(<3小时)的溶栓治疗除非能让更多患者获得,否则对死亡和致残情况不会产生重大影响。
确定缺血性卒中患者未接受静脉注射组织型纤溶酶原激活剂(IV TPA)的原因,并评估该疗法对缺血性卒中患者的可及性。
1996年10月至1999年12月期间,在一所大学教学医院前瞻性地确定连续的急性缺血性卒中患者。研究期间,还确定了在卡尔加里地区另外三家医院之一住院的其他缺血性卒中患者。采用牛津社区卒中计划分类法记录卒中类型和部位。
在该大学医院就诊的2165例卒中患者中,1168例(53.9%)被诊断为缺血性卒中,31.8%为颅内出血(脑内、蛛网膜下腔或硬膜下),13.9%为短暂性脑缺血发作(TIA)。就诊延迟超过3小时使73.1%(854/1168)的患者被排除。延迟的主要原因包括发病时间不确定(24.2%)、患者等待观察症状是否改善(29%)、由偏远医院转诊导致的延迟(8.9%)以及治疗医院无法到达(5.7%)。27%的缺血性卒中患者(314/1168)在症状发作后3小时内入院,其中84例(26.7%)患者接受了IV TPA。这组患者(<3小时)被排除的主要原因是轻度卒中(13.1%)、临床症状改善(18.2%)、认为不符合方案排除标准(13.6%)、急诊科转诊延迟(8.9%)以及严重合并症(8.3%)。那些被认为病情太轻或记录显示病情有显著改善的患者中,32%在出院时仍有残疾或在住院期间死亡。整个地区共有1806例缺血性卒中患者(入住卡尔加里所有四家医院)。在本研究期间,4.7%的患者接受了IV TPA。
大多数急性缺血性卒中患者无法接受TPA治疗,因为他们没有足够快地到达医院。在那些发病3小时内就诊的患者中,27%接受了治疗,但另有31%被排除,因为他们的症状要么被认为太轻,要么迅速改善。随后,这些患者中有三分之一最终出现残疾或死亡,这使得最初不进行治疗的决定受到质疑。